Parabilis Medicines Earnings Call Transcripts

Fiscal Year 2026

Morgan Stanley 24th Annual Global Healthcare Conference

The Helicon platform enables targeting of undruggable proteins, with Zolucatetide showing strong efficacy and safety in desmoid tumors and promising early results in FAP and ACP. Phase III trials, pipeline expansion, and a Regeneron partnership are underway, supported by $1.1B in cash.

Read full transcript →